Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed are an electrolyte for lithium secondary batteries including 10 to 50% by weight of a cyclic carbonate compound, and 50 to 90% by weight of a linear ester compound, based on the total weight of a non-aqueous solvent, wherein a content of ethyl propionate of the linear ester compound is 20 to 60% by weight, based on the total weight of the non-aqueous solvent, and a lithium secondary battery including the electrolyte and exhibiting superior low-temperature characteristics.

Disclosed are an electrolyte for lithium secondary batteries including 10 to 50% by weight of a cyclic carbonate compound, and 50 to 90% by weight of a linear ester compound, based on the total weight of a non-aqueous solvent, wherein a content of ethyl propionate of the linear ester compound is 20 to 60% by weight, based on the total weight of the non-aqueous solvent, and a lithium secondary battery including the electrolyte and exhibiting superior low-temperature characteristics.

Disclosed are an electrolyte for lithium secondary batteries including 10 to 50% by weight of a cyclic carbonate compound, and 50 to 90% by weight of a linear ester compound, based on the total weight of a non-aqueous solvent, wherein a content of ethyl propionate of the linear ester compound is 20 to 60% by weight, based on the total weight of the non-aqueous solvent, and a lithium secondary battery including the electrolyte and exhibiting superior low-temperature characteristics.

Disclosed are an electrolyte for lithium secondary batteries including 10 to 50% by weight of a cyclic carbonate compound, and 50 to 90% by weight of a linear ester compound, based on the total weight of a non-aqueous solvent, wherein a content of ethyl propionate of the linear ester compound is 20 to 60% by weight, based on the total weight of the non-aqueous solvent, and a lithium secondary battery including the electrolyte and exhibiting superior low-temperature characteristics.

The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

The present invention relates to a method for preparing a fluorinated methacrylate compound which can be used as a fluorine monomer for synthesizing a functional polymer having high oxygen permeability, water repellency and stain resistance. Specifically, the method can be carried out by a process of reacting an alcohol derivative and methacrylic acid anhydride in the presence of an imidazole-based base to obtain a fluorinated methacrylate. According to the preparation method of the present invention, since the reaction is carried out at room temperature and there is no process of removing the byproducts formed during the reaction, a high yield of fluorinated methacrylate can be obtained by a simple method within a short period of time.